Trade PT Kalbe Farma Tbk. - PTKFF CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Kalbe Farma Tbk PT ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 1,520.00-2,150.00 |
| Average Volume (10 days) | 29.19M |
| Average Volume (3 months) | 969.21M |
| Market Cap | 96,094.00B |
| P/E Ratio | 28.26 |
| Shares Outstanding | 46.26B |
| Revenue | 28,344.30B |
| EPS | 72.55 |
| Dividend (Yield %) | 1.70732 |
| Beta | 0.61 |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
PT Kalbe Farma Tbk. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, October 31, 2023 | ||
| Time (UTC) 10:59 | Country ID
| Event Q3 2023 Kalbe Farma Tbk PT Earnings Release Q3 2023 Kalbe Farma Tbk PT Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 28933500 | 26261200 | 23112700 | 22633500 | 21074300 |
| Revenue | 28933500 | 26261200 | 23112700 | 22633500 | 21074300 |
| Cost of Revenue, Total | 17498700 | 15157800 | 13062900 | 12607300 | 11337500 |
| Gross Profit | 11434800 | 11103400 | 10049700 | 10026200 | 9736770 |
| Total Operating Expense | 24537900 | 22250600 | 19560700 | 19333500 | 17861300 |
| Selling/General/Admin. Expenses, Total | 6237130 | 6080150 | 5530130 | 5740040 | 5516470 |
| Research & Development | 431804 | 487769 | 441755 | 511409 | 477039 |
| Depreciation / Amortization | 381501 | 380060 | 372916 | 298253 | 283444 |
| Interest Expense (Income) - Net Operating | -167938 | -283.254 | -72269.9 | 10497.2 | -29359 |
| Unusual Expense (Income) | -5181.88 | -15057.1 | 74238.9 | -5974 | -10367.7 |
| Other Operating Expenses, Total | 161814 | 160126 | 151022 | 171970 | 286514 |
| Operating Income | 4395630 | 4010630 | 3551930 | 3299960 | 3213030 |
| Interest Income (Expense), Net Non-Operating | 77099.7 | 145376 | 97420.9 | 112018 | 103454 |
| Other, Net | -13833.4 | -12736.5 | -21715.8 | -9365.12 | -10079.5 |
| Net Income Before Taxes | 4458900 | 4143260 | 3627630 | 3402620 | 3306400 |
| Net Income After Taxes | 3450080 | 3232010 | 2799620 | 2537600 | 2497260 |
| Minority Interest | -67873.6 | -48386.4 | -66362.6 | -30837.3 | -40132.9 |
| Net Income Before Extra. Items | 3382210 | 3183620 | 2733260 | 2506760 | 2457130 |
| Net Income | 3382210 | 3183620 | 2733260 | 2506760 | 2457130 |
| Income Available to Common Excl. Extra. Items | 3382210 | 3183620 | 2733260 | 2506760 | 2457130 |
| Income Available to Common Incl. Extra. Items | 3382210 | 3183620 | 2733260 | 2506760 | 2457130 |
| Diluted Net Income | 3382210 | 3183620 | 2733260 | 2506760 | 2457130 |
| Diluted Weighted Average Shares | 46515.9 | 46872.9 | 46873.4 | 46875.1 | 46875.1 |
| Diluted EPS Excluding Extraordinary Items | 72.7108 | 67.9202 | 58.3115 | 53.4775 | 52.4186 |
| Dividends per Share - Common Stock Primary Issue | 38 | 35 | 34 | 20 | 26 |
| Diluted Normalized EPS | 72.6246 | 67.6696 | 59.5338 | 53.3825 | 54.0426 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 7309770 | 7869160 | 7751730 | 7307180 | 6858880 |
| Revenue | 7309770 | 7869160 | 7751730 | 7307180 | 6858880 |
| Cost of Revenue, Total | 4440040 | 4722110 | 4919180 | 4411720 | 4046850 |
| Gross Profit | 2869730 | 3147050 | 2832550 | 2895470 | 2812030 |
| Total Operating Expense | 6469850 | 6783400 | 6539380 | 6205750 | 5842960 |
| Selling/General/Admin. Expenses, Total | 1691620 | 1761840 | 1492820 | 1543400 | 1607910 |
| Research & Development | 191685 | 134373 | 72426.9 | 130720 | 112016 |
| Depreciation / Amortization | 96264 | 94558.4 | 92320.1 | 98515.7 | 97905 |
| Interest Expense (Income) - Net Operating | 26104.9 | 34495.5 | -84359.3 | -33067.7 | -39025.3 |
| Unusual Expense (Income) | -88.0182 | -1091.01 | -2243.9 | -684.344 | |
| Other Operating Expenses, Total | 24136.1 | 36111 | 48081.4 | 56708.7 | 17989 |
| Operating Income | 839918 | 1085760 | 1212350 | 1101440 | 1015920 |
| Interest Income (Expense), Net Non-Operating | 5241.15 | 14610.8 | 15592.1 | 2378.35 | 30054 |
| Other, Net | -1710.26 | -4406.31 | -5491.62 | -3051.17 | -2546.06 |
| Net Income Before Taxes | 843449 | 1095960 | 1222450 | 1100760 | 1043430 |
| Net Income After Taxes | 662794 | 853873 | 915868 | 861463 | 820088 |
| Minority Interest | 10486 | 1843.8 | -19172.3 | -12897.8 | -18021.3 |
| Net Income Before Extra. Items | 673280 | 855717 | 896696 | 848565 | 802067 |
| Net Income | 673280 | 855717 | 896696 | 848565 | 802067 |
| Income Available to Common Excl. Extra. Items | 673280 | 855717 | 896696 | 848565 | 802067 |
| Income Available to Common Incl. Extra. Items | 673280 | 855717 | 896696 | 848565 | 802067 |
| Diluted Net Income | 673280 | 855717 | 896696 | 848565 | 802067 |
| Diluted Weighted Average Shares | 46515.9 | 46515.9 | 46515.9 | 46299.2 | 46464.7 |
| Diluted EPS Excluding Extraordinary Items | 14.4742 | 18.3962 | 19.2772 | 18.3279 | 17.2619 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 38 | 0 | 0 |
| Diluted Normalized EPS | 14.4742 | 18.3947 | 19.2596 | 18.2899 | 17.2503 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 16710200 | 15712200 | 13075300 | 11222500 | 10648300 |
| Cash and Short Term Investments | 4095080 | 6475170 | 5396250 | 3236110 | 3332050 |
| Cash | 1634560 | 2892560 | 2324850 | 980905 | 785338 |
| Cash & Equivalents | 2315210 | 3323690 | 2883080 | 2059580 | 2367990 |
| Short Term Investments | 145307 | 258923 | 188316 | 195619 | 178719 |
| Total Receivables, Net | 4787770 | 3545140 | 3594930 | 3697660 | 3373570 |
| Accounts Receivable - Trade, Net | 4613620 | 3431020 | 3477220 | 3572850 | 3255540 |
| Total Inventory | 7027360 | 5087300 | 3599750 | 3737980 | 3474590 |
| Prepaid Expenses | 731689 | 558900 | 435851 | 495586 | 419053 |
| Other Current Assets, Total | 68338.6 | 45695.8 | 48562.3 | 55162.9 | 49032.3 |
| Total Assets | 27241300 | 25666600 | 22564300 | 20264700 | 18146200 |
| Property/Plant/Equipment, Total - Net | 8333170 | 8322760 | 8310140 | 7666310 | 6252800 |
| Property/Plant/Equipment, Total - Gross | 13542600 | 12781100 | 12305200 | 11185700 | 9407830 |
| Accumulated Depreciation, Total | -5209440 | -4458300 | -3995050 | -3519370 | -3155030 |
| Goodwill, Net | 479347 | 209684 | 195226 | 293280 | 293280 |
| Intangibles, Net | 1026050 | 923048 | 464792 | 369273 | 140161 |
| Long Term Investments | 384543 | 303272 | 123338 | 91063.7 | 86106.4 |
| Note Receivable - Long Term | 93178.2 | 43576.1 | 35246.7 | 52685.5 | 54345.4 |
| Other Long Term Assets, Total | 214802 | 152086 | 360221 | 569619 | 671224 |
| Total Current Liabilities | 4431040 | 3534660 | 3176730 | 2577110 | 2286170 |
| Accounts Payable | 1996610 | 1667600 | 1240390 | 1215860 | 1289900 |
| Accrued Expenses | 601327 | 710937 | 481949 | 469464 | 301100 |
| Notes Payable/Short Term Debt | 705600 | 0 | 220500 | 149638 | 69154.7 |
| Current Port. of LT Debt/Capital Leases | 150219 | 93645.6 | 148764 | 19518.8 | 28251.2 |
| Other Current Liabilities, Total | 977278 | 1062480 | 1085130 | 722627 | 597764 |
| Total Liabilities | 6856100 | 6087110 | 5158770 | 4371600 | 3522750 |
| Total Long Term Debt | 311899 | 532510 | 788552 | 647688 | 260002 |
| Long Term Debt | 287031 | 490277 | 722819 | 647648 | 259831 |
| Capital Lease Obligations | 24868 | 42232.4 | 65732.4 | 40.8689 | 170.594 |
| Deferred Income Tax | 32500.2 | 19572.5 | 2590.63 | 241.581 | 129.249 |
| Minority Interest | 1712110 | 1686350 | 870549 | 812456 | 671137 |
| Other Liabilities, Total | 368547 | 314019 | 320350 | 334106 | 305313 |
| Total Equity | 20385200 | 19579500 | 17405500 | 15893100 | 14623500 |
| Common Stock | 468751 | 468751 | 468751 | 468751 | 468751 |
| Additional Paid-In Capital | -34118.7 | -34118.7 | -34118.7 | -34118.7 | -34118.7 |
| Retained Earnings (Accumulated Deficit) | 20497700 | 18746800 | 16875700 | 15361100 | 14073100 |
| Unrealized Gain (Loss) | 101896 | 73994.1 | 39111.3 | 56006.2 | 42056.4 |
| Other Equity, Total | 354924 | 326113 | 58181.5 | 41367.2 | 73659.9 |
| Total Liabilities & Shareholders’ Equity | 27241300 | 25666600 | 22564300 | 20264700 | 18146200 |
| Total Common Shares Outstanding | 46255.6 | 46872.9 | 46872.9 | 46875.1 | 46875.1 |
| Treasury Stock - Common | -1003970 | -2063.2 | -2063.2 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 17568000 | 16710200 | 16149400 | 15296900 | 16878100 |
| Cash and Short Term Investments | 3626610 | 4095080 | 4312080 | 4347760 | 6627180 |
| Cash | 1499350 | 1634560 | 2556490 | 2071030 | 2987500 |
| Cash & Equivalents | 1981600 | 2315210 | 1587420 | 2062460 | 3379570 |
| Short Term Investments | 145655 | 145307 | 168177 | 214274 | 260104 |
| Total Receivables, Net | 5390280 | 4787770 | 4459570 | 4171540 | 3953110 |
| Accounts Receivable - Trade, Net | 5247150 | 4613620 | 4319320 | 4025510 | 3820560 |
| Total Inventory | 7636260 | 7027360 | 6641200 | 6024020 | 5627150 |
| Prepaid Expenses | 862706 | 731689 | 675314 | 699379 | 612472 |
| Other Current Assets, Total | 52163.1 | 68338.6 | 61265 | 54162.3 | 58191.8 |
| Total Assets | 28239700 | 27241300 | 26187200 | 25263300 | 26861600 |
| Property/Plant/Equipment, Total - Net | 8334210 | 8333170 | 8270090 | 8220250 | 8332260 |
| Property/Plant/Equipment, Total - Gross | 13698700 | 13542600 | 13163200 | 12961400 | 12896100 |
| Accumulated Depreciation, Total | -5364480 | -5209440 | -4893160 | -4741160 | -4563860 |
| Goodwill, Net | 479347 | 479347 | 209684 | 209684 | 209684 |
| Intangibles, Net | 1032790 | 1026050 | 974465 | 956660 | 932918 |
| Long Term Investments | 511473 | 384543 | 367689 | 370980 | 315481 |
| Note Receivable - Long Term | 89220.7 | 93178.2 | 48413.5 | 51743.6 | 38212.4 |
| Other Long Term Assets, Total | 224618 | 214802 | 167382 | 157164 | 154935 |
| Total Current Liabilities | 4611540 | 4431040 | 4253260 | 3747340 | 4040390 |
| Accounts Payable | 2460570 | 1996610 | 1967160 | 1903690 | 1943820 |
| Accrued Expenses | 596959 | 601327 | 835694 | 805850 | 782814 |
| Notes Payable/Short Term Debt | 465400 | 705600 | 595000 | 110000 | 152000 |
| Current Port. of LT Debt/Capital Leases | 123860 | 150219 | 59194.1 | 72069.4 | 80334.4 |
| Other Current Liabilities, Total | 964748 | 977278 | 796212 | 855736 | 1081420 |
| Total Liabilities | 7039340 | 6856100 | 6716380 | 6213060 | 6619830 |
| Total Long Term Debt | 299310 | 311899 | 430753 | 439904 | 526909 |
| Long Term Debt | 280212 | 287031 | 400400 | 407668 | 486319 |
| Capital Lease Obligations | 19098.2 | 24868 | 30353 | 32235.9 | 40590.1 |
| Deferred Income Tax | 36340.7 | 32500.2 | 34226.9 | 28463.6 | 29580.9 |
| Minority Interest | 1720850 | 1712110 | 1678040 | 1679530 | 1704230 |
| Other Liabilities, Total | 371298 | 368547 | 320094 | 317822 | 318723 |
| Total Equity | 21200300 | 20385200 | 19470800 | 19050300 | 20241800 |
| Common Stock | 468751 | 468751 | 468751 | 468751 | 468751 |
| Additional Paid-In Capital | -34118.7 | -34118.7 | -34118.7 | -34118.7 | -34118.7 |
| Retained Earnings (Accumulated Deficit) | 21353500 | 20497700 | 19601000 | 18752500 | 19581700 |
| Treasury Stock - Common | -1003970 | -1003970 | -1003970 | -588396 | -179960 |
| Unrealized Gain (Loss) | 100713 | 101896 | 106015 | 106446 | 73912.6 |
| Other Equity, Total | 315516 | 354924 | 333061 | 345125 | 331433 |
| Total Liabilities & Shareholders’ Equity | 28239700 | 27241300 | 26187200 | 25263300 | 26861600 |
| Total Common Shares Outstanding | 46255.6 | 46255.6 | 46255.6 | 46508.8 | 46762.9 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Cash From Operating Activities | 1271890 | 2825950 | 4214740 | 2502970 | 2770780 |
| Cash Receipts | 31327400 | 28936600 | 25453500 | 24423100 | 22705200 |
| Cash Payments | -19106900 | -15917400 | -12407600 | -12316400 | -10798800 |
| Cash Taxes Paid | -1152780 | -965742 | -592189 | -818595 | -835148 |
| Changes in Working Capital | -9795850 | -9227540 | -8239060 | -8785210 | -8300460 |
| Cash From Investing Activities | -1370390 | -1056020 | -951215 | -1900540 | -1289830 |
| Capital Expenditures | -870100 | -1000870 | -1118200 | -1982930 | -1373030 |
| Other Investing Cash Flow Items, Total | -500290 | -55149.2 | 166989 | 82385.1 | 83202.9 |
| Cash From Financing Activities | -2405750 | -745176 | -1099710 | -706915 | -1139660 |
| Financing Cash Flow Items | -36101.4 | 1160700 | -80466.4 | 95863 | -9615.64 |
| Total Cash Dividends Paid | -1687680 | -1372680 | -1252230 | -1218750 | -1171880 |
| Issuance (Retirement) of Debt, Net | 319937 | -533194 | 235052 | 415975 | 41836 |
| Foreign Exchange Effects | 237776 | -16432.5 | 51263.6 | -51836.1 | 26952 |
| Net Change in Cash | -2266480 | 1008320 | 2215080 | -156324 | 368242 |
| Issuance (Retirement) of Stock, Net | -1001910 | 0 | -2063.2 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Cash From Operating Activities | 199521 | 1271890 | 577781 | 333318 | 336195 |
| Cash Receipts | 8114210 | 31327400 | 22539500 | 14717900 | 7336630 |
| Cash Payments | -4981690 | -19106900 | -13996500 | -8949310 | -4364840 |
| Cash Taxes Paid | -143623 | -1152780 | -777153 | -573965 | -162393 |
| Changes in Working Capital | -2789380 | -9795850 | -7188090 | -4861330 | -2473210 |
| Cash From Investing Activities | -297969 | -1370390 | -466102 | -258284 | -135934 |
| Capital Expenditures | -192626 | -870100 | -619489 | -350963 | -157932 |
| Other Investing Cash Flow Items, Total | -105343 | -500290 | 153387 | 92679.7 | 21998.4 |
| Cash From Financing Activities | -292885 | -2405750 | -2284310 | -2218480 | -61361.2 |
| Financing Cash Flow Items | -13090.2 | -36101.4 | -34727.4 | -23388.5 | -11647.8 |
| Issuance (Retirement) of Stock, Net | 0 | -1001910 | -1001910 | -586333 | -177897 |
| Issuance (Retirement) of Debt, Net | -279795 | 319937 | 440009 | -15426.7 | 128184 |
| Foreign Exchange Effects | -77482.9 | 237776 | 100285 | 60684.6 | 11923.4 |
| Net Change in Cash | -468815 | -2266480 | -2072340 | -2082760 | 150824 |
| Total Cash Dividends Paid | -1687680 | -1687680 | -1593330 |
PT Kalbe Farma Tbk. Company profile
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk is an Indonesia-based pharmaceutical company. The Company provides healthcare solution through its four business divisions: the prescription pharmaceutical division, consumer health, nutritional, and distribution and logistics divisions. Its Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over-the-counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments: infants, toddlers, children, pre-teenagers, teenagers, adults, pregnant and lactating women. Its Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
Financial summary
BRIEF: For the nine months ended 30 September 2021, KalbeFarma Tbk PT revenues increased 12% to RP19.099T. Netincome increased 13% to RP2.288T. Revenues reflectDistribution and Logistics segment increase of 24% toRP6.816T, Prescription Pharmaceutical segment increase of11% to RP4.191T, Domestic segment increase of 12% toRP18.214T, Export segment increase of 3% to RP884.72B.
Equity composition
01/2004, 2-for-1 stock split. 11/00 1.88-for-1 stock split.FY 04 Financials are restated. FY 05 Qs & 06 financials arerestated. FY 06 Qs are restated. 1 Nov 07, Co refiledQ3 07. No changes in financials. 24 March 09, Co refiledQ3 07. No changes in financials. 10/2012, Split 1-for-5 newshares (fac:5).
| Industry: | Pharmaceuticals (NEC) |
Gedung KALBE Let.Jend Suprato Kav. 4
JAKARTA
DKI JAKARTA
ID
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com